Mark J Ratain

Mark J Ratain

UNVERIFIED PROFILE

Are you Mark J Ratain?   Register this Author

Register author
Mark J Ratain

Mark J Ratain

Publications by authors named "Mark J Ratain"

Are you Mark J Ratain?   Register this Author

100Publications

2014Reads

22Profile Views

Immunotherapy and the A2A Adenosine Receptor: A Confounding Brew.

Clin Pharmacol Ther 2019 Sep 5;106(3):498-500. Epub 2019 Apr 5.

Department of Medicine, Section of Hematology/Oncology, The University of Chicago, Chicago, Illinois, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cpt.1428DOI Listing
September 2019

Assessment of patient knowledge and perceptions of pharmacogenomics before and after using a mock results patient web portal.

Clin Transl Sci 2019 Sep 6. Epub 2019 Sep 6.

Committee on Clinical Pharmacology and Pharmacogenomics, The University of Chicago, Chicago, Illinois, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/cts.12681DOI Listing
September 2019

The ImPreSS Trial: Implementation of Point-of-Care Pharmacogenomic Decision Support in Perioperative Care.

Clin Pharmacol Ther 2019 Aug 21. Epub 2019 Aug 21.

Committee on Clinical Pharmacology and Pharmacogenomics, The University of Chicago, Chicago, Illinois, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cpt.1567DOI Listing
August 2019

Prolonged Pharmacokinetic Interaction Between Capecitabine and a CYP2C9 Substrate, Celecoxib.

J Clin Pharmacol 2019 Jul 5. Epub 2019 Jul 5.

Department of Medicine, University of Chicago, Chicago, IL, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/jcph.1476DOI Listing
July 2019

Enhancing the Visibility and Prestige of Clinical Pharmacology as a Medical Subspecialty.

Authors:
Mark J Ratain

Clin Pharmacol Ther 2019 Jul 12. Epub 2019 Jul 12.

Department of Medicine, The University of Chicago, Chicago, Illinois, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cpt.1546DOI Listing
July 2019

Pharmacogenomic considerations for medications in the perioperative setting.

Pharmacogenomics 2019 Jul;20(11):813-827

Committee on Clinical Pharmacology & Pharmacogenomics, University of Chicago, Chicago, IL, 60637, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/pgs-2019-0040DOI Listing
July 2019

Interventional Pharmacoeconomics-A New Discipline for a Cost-Constrained Environment.

JAMA Oncol 2019 Jun 20. Epub 2019 Jun 20.

Value in Cancer Care Consortium, Ann Arbor, Michigan.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1001/jamaoncol.2019.1341DOI Listing
June 2019

The Role of Early-Phase Design-Letter.

Authors:
Mark J Ratain

Clin Cancer Res 2019 May;25(10):3190

Department of Medicine, Center for Personalized Therapeutics, Committee on Clinical Pharmacology and Pharmacogenomics, and Comprehensive Cancer Center, The University of Chicago, Chicago, Illinois.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-19-0350DOI Listing
May 2019

The Molecular Profiling Lottery: More Accuracy, Less Precision, and No Cost.

Authors:
Mark J Ratain

Clin Cancer Res 2019 Feb 4;25(4):1136-1138. Epub 2018 Dec 4.

Section of Hematology/Oncology, Department of Medicine, Center for Personalized Therapeutics, Committee on Clinical Pharmacology and Pharmacogenomics, and Comprehensive Cancer Center, The University of Chicago, Chicago, Illinois.

View Article

Download full-text PDF

Source
http://clincancerres.aacrjournals.org/lookup/doi/10.1158/107
Publisher Site
http://dx.doi.org/10.1158/1078-0432.CCR-18-3513DOI Listing
February 2019

Analysis of comprehensive pharmacogenomic profiling to impact in-hospital prescribing.

Pharmacogenet Genomics 2019 Feb;29(2):23-30

Center for Personalized Therapeutics.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/FPC.0000000000000346DOI Listing
February 2019

Reply to I.F. Tannock, P. Isaacsson Velho et al, M. Tiako Meyo et al, and F.J.S.H. Woei-A-Jin et al.

J Clin Oncol 2018 10 6;36(30):3064-3065. Epub 2018 Sep 6.

Russell Z. Szmulewitz, Walter M. Stadler, and Mark J. Ratain, The University of Chicago, Chicago, IL.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2018.79.3190DOI Listing
October 2018

Low-Dose Abiraterone With Food: Rebutting an Editorial.

J Clin Oncol 2018 10 6;36(30):3060-3061. Epub 2018 Sep 6.

Russell Z. Szmulewitz, Theodore Karrison, Walter M. Stadler, and Mark J. Ratain, The University of Chicago, Chicago, IL.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2018.79.3018DOI Listing
October 2018

A pharmacodynamic study of sirolimus and metformin in patients with advanced solid tumors.

Cancer Chemother Pharmacol 2018 08 9;82(2):309-317. Epub 2018 Jun 9.

Section of Hematology Oncology, Department of Medicine, University of Chicago, 5841 S. Maryland Avenue, MC 2115, Chicago, IL, 60637, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00280-018-3619-3DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6739841PMC
August 2018

Do Patients With Advanced Cancer Have the Ability to Make Informed Decisions for Participation in Phase I Clinical Trials?

J Clin Oncol 2018 08 9;36(24):2483-2491. Epub 2018 Jul 9.

Fay J. Hlubocky, Kristen E. Wroblewski, Mark J. Ratain, and Christopher K. Daugherty, The University of Chicago, Chicago; Halla S. Nimeiri and David Cella, Northwestern University, Evanston, IL; Greg A. Sachs, Indiana University and Regenstrief Institute, Indianapolis, IN; Eric R. Larson, Department of Veterans Affairs, Milwaukee, WI; and Jeffery M. Peppercorn, Massachusetts General Hospital, Dana-Farber Partners/Harvard Health System, Boston, MA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2017.73.3592DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6097830PMC
August 2018

Time Is Money: Optimizing the Scheduling of Nivolumab.

J Clin Oncol 2018 Aug 27:JCO1800045. Epub 2018 Aug 27.

Mark J. Ratain, The University of Chicago, Chicago, IL; and Daniel A. Goldstein, Rabin Medical Center, Petach Tikvah, Israel, and University of North Carolina at Chapel Hill, Chapel Hill, NC.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.18.00045DOI Listing
August 2018

Analyzing the clinical actionability of germline pharmacogenomic findings in oncology.

Cancer 2018 07 9;124(14):3052-3065. Epub 2018 May 9.

Center for Personalized Therapeutics, The University of Chicago, Chicago, Illinois.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cncr.31382DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6354920PMC
July 2018

Intraindividual Pharmacokinetic Variability: Focus on Small-Molecule Kinase Inhibitors.

Clin Pharmacol Ther 2018 06 1;103(6):956-958. Epub 2017 Dec 1.

University of Chicago, Chicago, Illinois, USA.

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1002/cpt.937
Publisher Site
http://dx.doi.org/10.1002/cpt.937DOI Listing
June 2018

Safety and Clinical Activity of Pembrolizumab and Multisite Stereotactic Body Radiotherapy in Patients With Advanced Solid Tumors.

J Clin Oncol 2018 06 13;36(16):1611-1618. Epub 2018 Feb 13.

Jason J. Luke, Jeffrey M. Lemons, Theodore G. Karrison, Sean P. Pitroda, James M. Melotek, Yuanyuan Zha, Hania A. Al-Hallaq, Ainhoa Arina, Nikolai N. Khodarev, Linda Janisch, Paul Chang, Jyoti D. Patel, Gini F. Fleming, John Moroney, Manish R. Sharma, Mark J. Ratain, Thomas F. Gajewski, Ralph R. Weichselbaum, and Steven J. Chmura, The University of Chicago, Chicago, IL; Julia R. White, The Ohio State University, Columbus, OH.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2017.76.2229DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5978468PMC
June 2018

Prospective International Randomized Phase II Study of Low-Dose Abiraterone With Food Versus Standard Dose Abiraterone In Castration-Resistant Prostate Cancer.

J Clin Oncol 2018 05 28;36(14):1389-1395. Epub 2018 Mar 28.

Russell Z. Szmulewitz, Abiola Ibraheem, Elia Martinez, Mark F. Kozloff, Chadi Nabhan, Theodore Karrison, Walter M. Stadler, and Mark J. Ratain, The University of Chicago, Chicago; Mark F. Kozloff, Ingalls Hospital, Harvey; Paul Fishkin, Illinois Cancer Care, Peoria, IL; Cody J. Peer and William D. Figg, National Cancer Institute, Rockville, MD; Bradley Carthon and R. Donald Harvey, Winship Cancer Institute of Emory University, Atlanta, GA; and Wei Peng Yong and Edmund Chiong, National University Cancer Institute, Singapore, Singapore.

View Article

Download full-text PDF

Source
http://ascopubs.org/doi/10.1200/JCO.2017.76.4381
Publisher Site
http://dx.doi.org/10.1200/JCO.2017.76.4381DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5941614PMC
May 2018

Clinical pharmacodynamic/exposure characterisation of the multikinase inhibitor ilorasertib (ABT-348) in a phase 1 dose-escalation trial.

Br J Cancer 2018 04 19;118(8):1042-1050. Epub 2018 Mar 19.

Department of Investigational Cancer Therapeutics, The University of Texas, MD Anderson Cancer Center, 1400 Holcombe Boulevard, Unit 455, Faculty Center 8th Floor, Houston, TX, 77030, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41416-018-0020-2DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5931107PMC
April 2018

Simplifying the use of pharmacogenomics in clinical practice: Building the genomic prescribing system.

J Biomed Inform 2017 Nov 28;75:110-121. Epub 2017 Sep 28.

Center for Personalized Therapeutics, University of Chicago, Chicago, IL, USA; Department of Medicine, University of Chicago, Chicago, IL, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jbi.2017.09.012DOI Listing
November 2017

Drug-Drug Interactions With Oral Antineoplastic Agents.

JAMA Oncol 2017 06;3(6):736-738

Department of Medicine and Committee on Clinical Pharmacology & Pharmacogenomics, University of Chicago, Chicago, Illinois.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1001/jamaoncol.2016.3323DOI Listing
June 2017

Assessment of patient perceptions of genomic testing to inform pharmacogenomic implementation.

Pharmacogenet Genomics 2017 05;27(5):179-189

aCenter for Personalized Therapeutics bPritzker School of Medicine cCommittee on Clinical Pharmacology and Pharmacogenomics dDepartment of Medicine, The University of Chicago, Chicago, Illinois, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/FPC.0000000000000275DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5478379PMC
May 2017

Burdensome Research Procedures in Trials: Why Less Is More.

J Natl Cancer Inst 2017 04;109(4)

Department of Medicine, Comprehensive Cancer Center, and Center for Personalized Therapeutics, The University of Chicago, Chicago, IL, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/jnci/djw315DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5756064PMC
April 2017

Genome-wide association studies of drug response and toxicity: an opportunity for genome medicine.

Nat Rev Drug Discov 2017 Jan 25;16(1). Epub 2016 Nov 25.

RIKEN Center for Integrative Medical Science, Yokohama 230-0045, Japan.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/nrd.2016.234DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5443656PMC
January 2017

Obviating the Need for Serial Biopsies Through Random Assignment.

J Clin Oncol 2017 01 31;35(2):260. Epub 2016 Oct 31.

Randy F. Sweis and Mark J. Ratain, University of Chicago, Chicago, IL.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2016.69.4471DOI Listing
January 2017

Reply to T.A. Yap et al.

J Clin Oncol 2016 07 2;34(20):2432-3. Epub 2016 May 2.

University of Chicago, Chicago, IL

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2016.67.6163DOI Listing
July 2016

In vitro glucuronidation of aprepitant: a moderate inhibitor of UGT2B7.

Xenobiotica 2015 8;45(11):990-8. Epub 2015 Jun 8.

a Department of Medicine , University of Chicago , Chicago , IL , USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3109/00498254.2015.1038743DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4844176PMC
June 2016

The impact of industry on oncology research and practice.

Am Soc Clin Oncol Educ Book 2015 :130-7

From the Massachusetts General Hospital Cancer Center, Boston, MA; University of Michigan, Ann Arbor, MI; Eli Lilly and Company, Indianapolis, IN; The University of Chicago, Chicago, IL.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.14694/EdBook_AM.2015.35.130DOI Listing
February 2016

Taking a Measured Approach to Toxicity Data in Phase I Oncology Clinical Trials.

Clin Cancer Res 2016 Feb 14;22(3):527-9. Epub 2015 Oct 14.

Department of Medicine and Committee on Clinical Pharmacology and Pharmacogenomics, University of Chicago, Chicago, Illinois.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-15-2005DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4738103PMC
February 2016

Analysis of Impact of Post-Treatment Biopsies in Phase I Clinical Trials.

J Clin Oncol 2016 Feb 14;34(4):369-74. Epub 2015 Dec 14.

Randy F. Sweis and Michael W. Drazer, University of Chicago; Mark J. Ratain, University of Chicago Medical Center, Chicago, IL.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2015.63.6126DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4872035PMC
February 2016

Casting doubt on the scientific utility of post-treatment biopsies in phase 1 trials.

Authors:
Mark J Ratain

Clin Adv Hematol Oncol 2016 Feb;14(2):78-9

The University of Chicago Medicine, Comprehensive Cancer Center, Chicago, Illinois.

View Article

Download full-text PDF

Source
February 2016

Serum C-Telopeptide Collagen Crosslinks and Plasma Soluble VEGFR2 as Pharmacodynamic Biomarkers in a Trial of Sequentially Administered Sunitinib and Cilengitide.

Clin Cancer Res 2015 Nov 21;21(22):5092-9. Epub 2015 Jul 21.

Section of Hematology/Oncology, Department of Medicine, The University of Chicago, Chicago, Illinois. Committee on Clinical Pharmacology and Pharmacogenomics, The University of Chicago, Chicago, Illinois. Comprehensive Cancer Center, The University of Chicago, Chicago, Illinois.

View Article

Download full-text PDF

Source
http://clincancerres.aacrjournals.org/cgi/doi/10.1158/1078-0
Publisher Site
http://dx.doi.org/10.1158/1078-0432.CCR-15-0427DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4677671PMC
November 2015

Participation in Cancer Pharmacogenomic Studies: A Study of 8456 Patients Registered to Clinical Trials in the Cancer and Leukemia Group B (Alliance).

J Natl Cancer Inst 2015 Oct 9;107(10). Epub 2015 Jul 9.

Personalized Medicine, Mission Cancer Care, Mission Health, Asheville, NC (LGD); Biostatistics Core, Lineberger Comprehensive Cancer Center, School of Medicine, University of North Carolina, Chapel Hill, NC (AMD); Alliance Statistics and Data Center, Duke University, Durham, NC (formerly the Cancer and Leukemia Group B Statistical and Data Management Center, Duke University, Durham, NC) (KO); GlaxoSmithKline, Research Triangle Park, NC (DW); Independent contractor, Williamsville, NY (KD); Department of Medicine and Center for Personalized Therapeutics, University of Chicago, Chicago, IL (PNF, MJR); DeBartolo Family Personalized Medicine Institute, Moffitt Cancer Center, Tampa, FL (HLM).

View Article

Download full-text PDF

Source
http://jnci.oxfordjournals.org/content/107/10/djv188.full.pd
Web Search
http://jnci.oxfordjournals.org/lookup/doi/10.1093/jnci/djv18
Publisher Site
http://dx.doi.org/10.1093/jnci/djv188DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5758036PMC
October 2015

First-in-human, phase I study of elisidepsin (PM02734) administered as a 30-min or as a 3-hour intravenous infusion every three weeks in patients with advanced solid tumors.

Invest New Drugs 2015 Aug 8;33(4):901-10. Epub 2015 May 8.

Department of Medicine, University of Chicago, MC2115, 5841 South Maryland Avenue, Chicago, IL, 60637, USA,

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10637-015-0247-1DOI Listing
August 2015

Glucuronidation of OTS167 in Humans Is Catalyzed by UDP-Glucuronosyltransferases UGT1A1, UGT1A3, UGT1A8, and UGT1A10.

Drug Metab Dispos 2015 Jul 13;43(7):928-35. Epub 2015 Apr 13.

Department of Medicine, University of Chicago, Chicago, Illinois

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1124/dmd.115.063271DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4468433PMC
July 2015

Evidence for Clinical Implementation of Pharmacogenomics in Cardiac Drugs.

Mayo Clin Proc 2015 Jun;90(6):716-29

Center for Personalized Therapeutics, The University of Chicago, Chicago, IL; Department of Medicine, The University of Chicago, Chicago, IL; Committee on Clinical Pharmacology and Pharmacogenomics, The University of Chicago, Chicago, IL. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.mayocp.2015.03.016DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4475352PMC
June 2015

User beware: we need more science and less art when measuring financial toxicity in oncology.

J Clin Oncol 2015 Apr 2;33(12):1414-5. Epub 2015 Mar 2.

The University of Chicago, Chicago, IL.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2014.59.4986DOI Listing
April 2015

Redefining the primary objective of phase I oncology trials.

Authors:
Mark J Ratain

Nat Rev Clin Oncol 2015 Mar 9;12(3):126. Epub 2014 Sep 9.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/nrclinonc.2014.157DOI Listing
March 2015

Circadian variation in plasma 5-fluorouracil concentrations during a 24 hour constant-rate infusion.

BMC Cancer 2015 Feb 18;15:69. Epub 2015 Feb 18.

Section of Hematology/Oncology, Department of Medicine, 5841 South Maryland Avenue, MC 2115, Chicago, IL, 60637, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s12885-015-1075-6DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4336691PMC
February 2015

UGT1A and UGT2B genetic variation alters nicotine and nitrosamine glucuronidation in european and african american smokers.

Cancer Epidemiol Biomarkers Prev 2015 Jan 2;24(1):94-104. Epub 2014 Oct 2.

Department of Pharmacology and Toxicology, University of Toronto, Toronto, Ontario, Canada. Campbell Family Mental Health Research Institute, Centre for Addiction and Mental Health, University of Toronto, Toronto, Ontario, Canada. Department of Psychiatry, University of Toronto, Toronto, Ontario, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1055-9965.EPI-14-0804DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4294984PMC
January 2015

Identification of a variant in KDR associated with serum VEGFR2 and pharmacodynamics of Pazopanib.

Clin Cancer Res 2015 Jan 19;21(2):365-72. Epub 2014 Nov 19.

Program in Personalized and Genomic Medicine, and Division of Endocrinology, Diabetes and Nutrition, School of Medicine, University of Maryland, Baltimore, Maryland. Geriatric Research and Education Clinical Center, Baltimore Veterans Administration Medical Center, Baltimore, Maryland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-14-1683DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4323272PMC
January 2015

Loss of heterozygosity at the CYP2D6 locus in breast cancer: implications for germline pharmacogenetic studies.

J Natl Cancer Inst 2014 Dec 8;107(2). Epub 2014 Dec 8.

Department of Oncology (MPG, MMA, JNI), Department of Health Sciences Research (VJS, KRK), and Department of Molecular Pharmacology and Experimental Therapeutics (MPG, SLS, MK, MMA), Mayo Clinic, Rochester, MN; Department of Genetics, University of North Carolina, Chapel Hill, NC (GOS, CMP); Center for Personalized Therapeutics, University of Chicago, Chicago, IL (YN, NJC, MJR); Foundation Medicine Inc., Cambridge, MA (JXS, PJS, VAM, JSR, RY); Novartis Pharmaceuticals Corporation, East Hanover, NJ (DC); Department of Pathology and Laboratory Medicine, Albany Medical College, Albany, NY (JSR); Division of Hematology/Oncology, Vanderbilt University, Nashville, TN (HG); Department of Breast Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX (AMGA, OB); Department Breast Cancer Susceptibility and Pharmacogenomics, Dr Margarete Fischer-Bosch-Institute of Clinical Pharmacology, Stuttgart, University Tuebingen, German Cancer Consortium (DKTK) and German Cancer Research (DKTK), Heidelberg, Germany (HB).Current affiliation of H. Gomez: Departamento de Medicina Oncologica, Instituto Nacional de Enfermedades Neoplasicas, Lima, Peru.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/jnci/dju401DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4565524PMC
December 2014

The development of a financial toxicity patient-reported outcome in cancer: The COST measure.

Cancer 2014 Oct 20;120(20):3245-53. Epub 2014 Jun 20.

Section of Hematology/Oncology, Department of Medicine, The University of Chicago Medicine, Chicago, Illinois.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cncr.28814DOI Listing
October 2014

Targeted therapies: redefining the primary objective of phase I oncology trials.

Authors:
Mark J Ratain

Nat Rev Clin Oncol 2014 Sep 5;11(9):503-4. Epub 2014 Aug 5.

Department of Medicine, Comprehensive Cancer Center, and Center for Personalized Therapeutics, The University of Chicago, 5841 South Maryland Avenue, MC2115, Chicago, IL 60637, USA.

View Article

Download full-text PDF

Source
http://www.nature.com/articles/nrclinonc.2014.135
Publisher Site
http://dx.doi.org/10.1038/nrclinonc.2014.135DOI Listing
September 2014

Forecasting unanticipated consequences of "The Sunshine Act": mostly cloudy.

Authors:
Mark J Ratain

J Clin Oncol 2014 Aug 16;32(22):2293-5. Epub 2014 Jun 16.

The University of Chicago, Chicago, IL

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2014.55.4592DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4876333PMC
August 2014

Dose-finding and pharmacokinetic study to optimize the dosing of irinotecan according to the UGT1A1 genotype of patients with cancer.

J Clin Oncol 2014 Aug 23;32(22):2328-34. Epub 2014 Jun 23.

Federico Innocenti, Richard L. Schilsky, Jacqueline Ramírez, Linda Janisch, Samir Undevia, Larry K. House, Soma Das, Kehua Wu, Michelle Turcich, Theodore Karrison, Michael L. Maitland, Ravi Salgia, and Mark J. Ratain, University of Chicago, Chicago; and Robert Marsh, NorthShore University Health System, Evanston, IL.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2014.55.2307DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4105486PMC
August 2014

Incorporating biomarkers into drug labeling.

Authors:
Mark J Ratain

Clin Adv Hematol Oncol 2014 Aug;12(8):525-8

The University of Chicago, Chicago, Illinois.

View Article

Download full-text PDF

Source
August 2014

First-in-human phase I study of Lurbinectedin (PM01183) in patients with advanced solid tumors.

Clin Cancer Res 2014 Apr 21;20(8):2205-14. Epub 2014 Feb 21.

Authors' Affiliations: Vall d'Hebron University Hospital and Vall d'Hebron Institute of Oncology (VHIO), Universitat Autònoma de Barcelona, Barcelona; PharmaMar, S.A., Colmenar Viejo, Madrid, Spain; and Department of Medicine, The University of Chicago, Chicago, Illinois.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-13-1880DOI Listing
April 2014

Re: Concordance between CYP2D6 genotypes obtained from tumor-derived and germline DNA.

J Natl Cancer Inst 2014 Apr 3;106(5). Epub 2014 Apr 3.

Affiliations of authors: Department of Oncology (MPG, JNI) and Department of Molecular Pharmacology and Experimental Therapeutics (MPG, RW), Mayo Clinic, Rochester, MN; Dr Margarete Fischer-Bosch-Institute of Clinical Pharmacology, Stuttgart, Germany (HB); The University of Chicago, Chicago, IL (MJR, NJC, YN).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/jnci/dju063DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4580553PMC
April 2014

Vemurafenib oral bioavailability: an insoluble problem.

J Clin Pharmacol 2014 Apr;54(4):375-7

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/jcph.277DOI Listing
April 2014

Phase I dose-escalation study of onartuzumab as a single agent and in combination with bevacizumab in patients with advanced solid malignancies.

Clin Cancer Res 2014 Mar 3;20(6):1666-75. Epub 2014 Feb 3.

Authors' Affiliations: Section of Hematology/Oncology, Department of Medicine, The University of Chicago, Chicago, Illinois; Genentech, Inc., South San Francisco, California; and Rutgers Cancer Institute of New Jersey, Rutgers, The State University of New Jersey, New Brunswick, New Jersey.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-13-2070DOI Listing
March 2014

A pharmacogenetic study of aldehyde oxidase I in patients treated with XK469.

Pharmacogenet Genomics 2014 Feb;24(2):129-32

aDepartment of Medicine, The University of Chicago, Chicago, Illinois bDepartment of Biostatistics and Bioinformatics, Duke University Medical Center, Durham, North Carolina, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/FPC.0000000000000023DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3901533PMC
February 2014

Germline variants and advanced colorectal adenomas: adenoma prevention with celecoxib trial genome-wide association study.

Clin Cancer Res 2013 Dec 1;19(23):6430-7. Epub 2013 Oct 1.

Authors' Affiliations: Department of Surgery, Division of Surgical Oncology, Center for Genomic Medicine, Channing Laboratory, Brigham and Women's Hospital, Boston, Massachusetts; Genome Center and Department of Biochemistry and Molecular Medicine, University of California, Davis, California; Department of Epidemiology and Statistics, Memorial Sloan-Kettering Cancer Center, New York; RIKEN Center for Genomic Medicine, Tokyo, Japan; Colon Cancer Genetics Group, Institute of Genetics and Molecular Medicine, University of Edinburgh and MRC Human Genetics Unit, Edinburgh; Section of Cancer Genetics, Institute of Cancer Research, Sutton, United Kingdom; Ludwig Colon Cancer Initiative Laboratory, Ludwig Institute for Cancer Research, Royal Melbourne Hospital, Parkville; Genetic and Molecular Epidemiology Laboratories, and Familial Cancer laboratory, Queensland Institute of Medical Research, Brisbane; Centre for Eye Research Australia, University of Melbourne, Royal Victorian Eye and Ear Hospital, East Melbourne, Australia; and Department of Medicine, University of Chicago, Chicago, Illinois.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-13-0550DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4037290PMC
December 2013

Evaluation of utility of pharmacokinetic studies in phase I trials of two oncology drugs.

Clin Cancer Res 2013 Nov 20;19(21):6039-43. Epub 2013 Sep 20.

Authors' Affiliations: Departments of Medicine, Committee on Clinical Pharmacology and Pharmacogenomics, Comprehensive Cancer Center, The University of Chicago, Chicago, Illinois.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-13-0597DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3832109PMC
November 2013

Hepatocyte nuclear factor 1 regulates the expression of the organic cation transporter 1 via binding to an evolutionary conserved region in intron 1 of the OCT1 gene.

J Pharmacol Exp Ther 2013 Oct 6;347(1):181-92. Epub 2013 Aug 6.

Institute of Clinical Pharmacology, University Medical Center, Georg-August-Universität Göttingen, Germany (V.P.O., K.B., K.J., J.B., M.V.T.); and Department of Medicine, Section of Hematology/Oncology, The University of Chicago, Chicago, Illinois (J.R., M.J.R.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1124/jpet.113.206359DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3781413PMC
October 2013

Institutional Profile: University of Chicago Center for Personalized Therapeutics: research, education and implementation science.

Pharmacogenomics 2013 Sep;14(12):1383-7

Committee on Clinical Pharmacology & Pharmacogenomics, 900 E 57th Street, KCBD 7100, University of Chicago, Chicago, IL 60637, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/pgs.13.134DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4022693PMC
September 2013

Tumour heterogeneity in the clinic.

Nature 2013 Sep;501(7467):355-64

Princess Margaret Cancer Centre, University Health Network, Division of Medical Oncology and Hematology, Toronto, Ontario, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/nature12627DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5224525PMC
September 2013

Unmet needs in preventing adverse drug-drug interactions.

Clin Adv Hematol Oncol 2013 Aug;11(8):520-1

Postdoctoral Fellow Committee on Clinical Pharmacology and Pharmacogenomics The University of Chicago Chicago, Illinois.

View Article

Download full-text PDF

Source
August 2013

Unsupported off-label chemotherapy in metastatic colon cancer.

BMC Health Serv Res 2012 Dec 29;12:481. Epub 2012 Dec 29.

Section of Hematology/Oncology, The University of Chicago Medicine, Chicago, IL, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/1472-6963-12-481DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3544564PMC
December 2012